Compare Stocks → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APLTNASDAQ:ATNFNASDAQ:CLRBNASDAQ:LABP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$4.23-1.9%$5.89$1.18▼$9.39$483.24M1.811.92 million shs568,522 shsATNF180 Life Sciences$1.77-2.7%$2.86$1.33▼$27.93$1.50M0.44106,529 shs15,531 shsCLRBCellectar Biosciences$3.02-1.3%$3.63$1.33▼$4.45$97.43M0.921.65 million shs678,612 shsLABPLandos Biopharma$22.35+0.8%$13.74$2.50▼$22.84$69.73M0.1421,831 shs3,928 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-3.36%-10.77%-36.15%+47.60%+220.71%ATNF180 Life Sciences-4.21%-4.71%-13.75%-56.06%-91.29%CLRBCellectar Biosciences-1.61%-4.67%-20.93%-14.76%+106.76%LABPLandos Biopharma+0.95%+3.18%+4.44%+367.78%+671.03%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.6633 of 5 stars4.54.00.04.70.03.30.6ATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACLRBCellectar Biosciences2.2158 of 5 stars3.54.00.00.02.50.00.6LABPLandos Biopharma0.3228 of 5 stars1.05.00.00.00.60.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics3.00Buy$11.00160.05% UpsideATNF180 Life SciencesN/AN/AN/AN/ACLRBCellectar Biosciences3.00Buy$20.00562.25% UpsideLABPLandos Biopharma2.00Hold$20.42-8.64% DownsideCurrent Analyst RatingsLatest CLRB, APLT, LABP, and ATNF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.004/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.423/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/26/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/15/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/6/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $12.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/22/2024APLTApplied TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/22/2024APLTApplied TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/16/2024APLTApplied TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$9.99M48.37N/AN/A($0.20) per share-21.15ATNF180 Life SciencesN/AN/AN/AN/A($0.24) per shareN/ACLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/ALABPLandos Biopharma$18M3.87N/AN/A$10.20 per share2.19Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)ATNF180 Life Sciences-$19.93MN/A0.00∞N/AN/A-320.26%-112.07%5/20/2024 (Estimated)CLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)LABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%5/10/2024 (Estimated)Latest CLRB, APLT, LABP, and ATNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023CLRBCellectar Biosciences-$0.59-$0.66-$0.07-$0.92N/AN/A3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/A3/6/2024Q4 2023APLTApplied Therapeutics-$0.15-$0.33-$0.18-$0.33N/A($0.67) millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.760.76ATNF180 Life SciencesN/A0.720.72CLRBCellectar BiosciencesN/A0.810.81LABPLandos BiopharmaN/A6.096.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%ATNF180 Life Sciences4.07%CLRBCellectar Biosciences16.41%LABPLandos Biopharma49.06%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics19.10%ATNF180 Life Sciences4.10%CLRBCellectar Biosciences4.60%LABPLandos Biopharma1.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics25114.24 million85.66 millionOptionableATNF180 Life Sciences5850,000818,000No DataCLRBCellectar Biosciences2032.26 million30.78 millionOptionableLABPLandos Biopharma193.12 million3.08 millionNot OptionableCLRB, APLT, LABP, and ATNF HeadlinesSourceHeadlineLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96msn.com - April 17 at 10:47 AMStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieprnewswire.com - April 16 at 3:32 PMLandos Biopharma, Inc. (NASDAQ:LABP) Short Interest Updatemarketbeat.com - April 10 at 6:50 PMLandos Biopharma, Inc. Expected to Earn Q1 2024 Earnings of ($0.88) Per Share (NASDAQ:LABP)marketbeat.com - April 3 at 6:00 AMHC Wainwright Reiterates Neutral Rating for Landos Biopharma (NASDAQ:LABP)marketbeat.com - April 1 at 8:30 AMLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPbusinesswire.com - March 27 at 6:04 PMLandos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseasesfinanznachrichten.de - March 27 at 7:38 AMLeerink Partners Remains a Hold on Landos Biopharma (LABP)markets.businessinsider.com - March 27 at 7:38 AMSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPprnewswire.com - March 26 at 7:47 PMAbbVie grabs a wrench to add immunology-focused Landos Biopharma for $137.5Mfiercebiotech.com - March 26 at 3:06 AMAbbVie buys Landos for up to $212.5 millionthepharmaletter.com - March 26 at 3:06 AMAbbVie To Acquire Landos Biopharma At $20.42/share In Cashmarkets.businessinsider.com - March 26 at 3:06 AMAbbVie to buy Landos Biopharma for $137 millionbizjournals.com - March 26 at 3:06 AMWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?finance.yahoo.com - March 26 at 3:06 AMWhy Is Landos Biopharma (LABP) Stock Up 168% Today?investorplace.com - March 25 at 12:17 PMShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieprnewswire.com - March 25 at 12:03 PMLABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholdersbusinesswire.com - March 25 at 11:36 AMAbbVie to buy Landos to expand pipeline of immunity-related illnessesreuters.com - March 25 at 8:39 AMAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseasesprnewswire.com - March 25 at 8:31 AMAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseasesglobenewswire.com - March 25 at 8:30 AMLABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023investorplace.com - March 21 at 2:05 PMLandos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Resultsfinanznachrichten.de - March 21 at 11:34 AMRecap: Landos Biopharma Q4 Earningsbenzinga.com - March 21 at 11:34 AMLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Resultsglobenewswire.com - March 21 at 8:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied TherapeuticsNASDAQ:APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.180 Life SciencesNASDAQ:ATNF180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Cellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.